Oireachtas Joint and Select Committees

Wednesday, 30 January 2019

Joint Oireachtas Committee on Health

Implications for Health Sector of United Kingdom's Withdrawal from the EU: Discussion (Resumed)

Mr. John Hennessy:

To add a quick point to that, high-volume, low-priced medicines are a very specific part of the contingency planning. I echo Dr. Nolan's point that we do not have huge concerns in the short term, but in the medium to longer term there may be issues around continuity of supply and perhaps price implications, seeing as Ireland is such a small component of the market for those products. My colleague, Mr. Swords, has been working on a number of these areas, including medical-surgical supplies, in order to ensure continuity and availability, but there are no major concerns emerging in the short term. In the medium to longer term we will need to monitor matters carefully. As Dr. Nolan mentioned, however, of their nature, there is interchangeability and alternatives may have to be sourced, but we are particularly conscious that there are high numbers of patients, particularly those with chronic illnesses, who are on these medicines who would have become reliant on or used to the same products for perhaps a considerable amount of time. We are not underestimating the issue for a moment but it represents more of a longer-term concern rather than a short-term one in the context of Brexit.

Deputy Durkan referred to children. The treatment abroad scheme covers this pretty extensively for both adults and children. However, children represent a niche in the context of transplant services in particular. We have a very close relationship with a small number of UK tertiary sites that provide these specialist services. The numbers would not be sufficient to provide that level of service within the island of Ireland. Our planning focus - and there has been very extensive planning on this - is on ensuring that this access route remains open and available, and the agreements with the individual sites in the UK are developed in order to ensure that post Brexit. As I said, though, the particular concern, and where there would not necessarily be readily available alternatives to UK sites, is in the area of transplants for children.

I do not know if Mr. Hennessy wishes to add anything.